Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMOOTHIE: Single vs dual antiplatelet therapy after paclitaxel-eluting femoropopliteal EVT
jRCTs031220617Recruiting
- Sponsor
- Peripheral Vascular Regeneration Research Group
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of aspirin and clopidogrel in arteriosclerosis obliterans (3 arms), sponsored by Peripheral Vascular Regeneration Research Group. Primary endpoint: Primary patency rate of target lesions at 12 months. Started Dec 2022; status: recruiting.
02
Drugs
aspirinclopidogrel
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCTs031220617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220617.